Efficacy and Safety Profile of Ivosidenib in the Management of Patients with Acute Myeloid Leukemia (AML): An Update on the Emerging Evidence
Galia Stemer,1 Jacob M Rowe,2– 4 Yishai Ofran2,4 1Institute of Hematology, Ha’Emek Medical Center, Afula, Israel; 2Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel; 3Department of Hematology, Shaare Zedek Medical Center, Jerusalem...
Guardado en:
Autores principales: | Stemer G, Rowe JM, Ofran Y |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c5b5aacb1fa546c1b7c4b95517c9ddd0 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
IDH1-mutated relapsed or refractory AML: current challenges and future prospects
por: Megías-Vericat JE, et al.
Publicado: (2019) -
Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives
por: Anagnostou T, et al.
Publicado: (2017) -
Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells
por: Carrà G, et al.
Publicado: (2019) -
NEW ADVANCES IN PEDIATRIC ACUTE MYELOID LEUKEMIA
por: Özlem Tüfekçi
Publicado: (2021) -
EXPERIENCE OF GLASDEGIB IN PATIENTS WITH ELDERLY ACUTE MYELOID LEUKEMIA
por: Nanişe Gizem FENER, et al.
Publicado: (2021)